UNJ Stock Chart & Stats
€0.88
€0.02(2.04%)
At close: 4:00 PM EDT
€0.88
€0.02(2.04%)
Day’s Range― - ―
52-Week Range€0.83 - €1.67
Previous CloseN/A
Volume0.00
Average Volume (3M)90.00
Market Cap
€1.68B
Enterprise Value€10.04K
Total Cash (Recent Filing)€11.73B
Total Debt (Recent Filing)€5.95B
Price to Earnings (P/E)23.9
Beta0.66
Next Earnings
Mar 30, 2027EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding1,970,276,500
10 Day Avg. Volume0
30 Day Avg. Volume90
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)1.13
Price to Sales (P/S)1.49
P/FCF Ratio22.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.41Price Target Upside59.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.06
Revenue Forecast (FY)€1.37B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetModerate leverage and steadily growing equity provide financial resilience and flexibility. This supports continued investment in pharmaceutical products and capacity while reducing the balance-sheet strain that can limit operations during weaker industry or company-specific periods.
Established Pharmaceutical ProfitabilityA healthy gross margin indicates that the company retains meaningful economics across its pharmaceutical portfolio. Sustained absolute profitability can support research, regulatory work, manufacturing operations, and commercial investment even while recent earnings growth has slowed.
Integrated Two-stream Business ModelCombining finished medicines with APIs and intermediates gives the company exposure to multiple pharmaceutical revenue pools. Internal API use can support product production, while external sales add another route to monetize manufacturing capability and industry demand.
Bears Say
Recent Revenue ContractionThe recent revenue decline interrupts the stronger expansion recorded from 2020 to 2023 and signals weaker demand, market penetration, or product mix. If sustained, slower top-line growth can reduce operating leverage and constrain the resources available for portfolio development.
Margin And Return CompressionLower margins and ROE show that the company is generating less profit from both sales and its capital base. Persistent compression would weaken earnings quality, reduce reinvestment efficiency, and make recovery dependent on renewed revenue growth or improved operating performance.
Weak And Volatile Cash ConversionLow free-cash-flow conversion means reported profits are translating less consistently into cash available for reinvestment, debt service, or shareholder returns. Volatility also makes capital planning harder and reduces the durability of earnings as a funding source.
The United Laboratories International Holdings News
UNJ FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was €0.83 and its highest was €1.67 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is €1.68B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Mar 30, 2027 which is in 192 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Aug 31, 2026. The company reported €0.023 earnings per share for the quarter, beating the consensus estimate of €0.017 by €0.006.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited does not currently pay dividends.
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.03.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,970,276,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of €0.023 in its last earnings report, beating expectations of €0.017. Following the earnings report the stock price went down -3.279%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in DE:UNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
The United Laboratories International Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.10%
12-Months-Change
Fundamentals
Return on Equity
3.64%
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.
UNJ Stock 12 Month Forecast
Average Price Target
€1.41
▲(59.92% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―